Limba
|
Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-METand SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).
Price | 16.249,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-METand SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC). |